Novartis and Novo helped provide $40m for the autoimmune disease therapy developer that supported its acquisition of joint venture Kanyos Bio.
Switzerland-based autoimmune disease drug developer Anokion has closed a $40m series B round featuring Novartis Venture Fund and Novo Ventures, respective subsidiaries of pharmaceutical firms Novartis and Novo.
Venture capital firm Versant Ventures and undisclosed private investors also participated in the round, which followed $37.4m in series A funding from the same investors in 2014.
Anokion is developing therapies that are intended to restore normal levels of immune tolerance to patients suffering from autoimmune diseases such as multiple sclerosis,…
